A fluorescence-based assay for monitoring clinical drug resistance

Journal of Clinical Pathology

Volumn 65, Issue 11, 2012, Pages 1003-1007

  Deniset Besseau, Ariane ^a   Miannay, François Alexandre ^a,b   Laplace Builhé, Corinne ^c   Vielh, Philippe ^c   Lécart, Sandrine ^b   Lwaleed, Bashir A ^d   Eschwege, Pascal ^e,f   Fontaine Aupart, Marie Pierre ^a,b  

^a INSTITUT DES SCIENCES MOLÉCULAIRES D ORSAY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e CHU NANCY BRABOIS   (France)

^f Antony Private Hospital   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; VINBLASTINE SULFATE;

ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DRUG DISTRIBUTION; DRUG MONITORING; DRUG UPTAKE; FLUORESCENCE; FLUORESCENCE SPECTROSCOPY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; NEEDLE BIOPSY; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; URINE CYTOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, FINE-NEEDLE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL NUCLEUS; CISPLATIN; CYTOPLASM; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLUORESCENCE; HUMANS; METHOTREXATE; OPTICAL IMAGING; PREDICTIVE VALUE OF TESTS; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 84867911302     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-200787     Document Type: Article

References (32)

1. Simon SM, Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 1994;91:3497-504. (Pubitemid 24139457)
2. Zijlstra JG, de Vries EG, Mulder NH. Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. 1987;47:1780-4.
3. Zijlstra JG, de Vries EG, Mulder NH. Drug resistance in medical oncology. Neth J Med 1987;30:85-93. (Pubitemid 17123589)
4. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000;11:265-83.
5. Ambudkar SV, et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999;39:361-98. (Pubitemid 29222564)
6. Coley HM, Twentyman PR, Workman P. The efflux of anthracyclines in multidrug-resistant cell lines. Biochem Pharmacol 1993;46:1317-26. (Pubitemid 23319299)
7. Praet M, Stryckmans P, Ruysschaert JM. Cellular uptake, cytotoxicity, and transport kinetics of anthracyclines in human sensitive and multidrug-resistant K562 cells. Biochem Pharmacol 1996;51:1341-8. (Pubitemid 26142858)
8. Schuurhuis GJ, et al . Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells. 1989;81:1887-92.
9. Sato H, et al. MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. Br J Haematol 1990;75:340-5. (Pubitemid 20233277)
10. Sugawara I. Expression and functions of P-glycoprotein (mdr1 gene product) in normal and malignant tissues. Acta Pathologica Japonica 1990;40:545-53. (Pubitemid 20328971)
11. Flens MJ, et al. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res 1994;54:4557-63. (Pubitemid 24276470)
12. Moriyama M, et al. Immunological diagnosis of multidrug resistant cancer in urological malignancies. Gan To Kagaku Ryoho 1990;17:502-8. (Pubitemid 20364264)
13. Broxterman HJ, et al. Immunohistochemical detection of P-glycoprotein in human tumor cells with a low degree of drug resistance. Int J Cancer 1989;43:340-3. (Pubitemid 19062434)
14. Broxterman HJ, et al. Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. 1996;87:4809-16.
15. Morjani H, et al. Evaluation of multidrug resistance phenotype on medullary specimens from patients with acute leukemia by determination of nuclear effl ux of tetrahydropyranyl-doxorubicin. Approach by confocal laser microspectrofluorometry. Ann Biol Clin 1996;54:9-15. (Pubitemid 26084984)
16. Schuurhuis GJ, et al. Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. 1991;64:857-61.
17. Soga N, Arima K, Sugimura Y. Adjuvant methotrexate, vinblastine, adriamycin and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma. Int J Urol 2008;15:800-3.
18. de Lange JH, et al. Quantification by laser scan microscopy of intracellular doxorubicin distribution. Cytometry 1992;13:571-6.
19. Coley HM, Amos WB, Twentyman PR, et al . Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines. Br J Cancer 1993;67:1316-23. (Pubitemid 23172871)
20. Schuurhuis GJ, et al. Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells. Br J Cancer 1993;68:898-908. (Pubitemid 23315221)
21. Arancia G, Calcabrini A, Meschini S, et al. Intracellular distribution of anthracyclines in drug resistant cells. Cytotechnology 1998;27:95-111. (Pubitemid 29025463)
22. Hsu CY, Lai PS, Pai CL, et al. Enhanced cytotoxicity of doxorubicin by micellar photosensitizer-mediated photochemical internalization in drug-resistant MCF-7 cells. IFMBE Proceedings 2008;23:1451-4.
23. Luk CK, Tannock IF. Flow cytometric analysis of doxorubicin accumulation in cells from human and rodent cell lines. 1989;81:55-9.
24. Manfait M, Robert J. Confocal microscopy of idarubicin localisation. 1997;76:136.
25. Lewin JM, Lwaleed BA, Cooper AJ, et al. The direct effect of nuclear pores on nuclear chemotherapeutic concentration in multidrug resistant bladder cancer: the nuclear sparing phenomenon. J Urol 2007;177:1526-30. (Pubitemid 46436015)
26. Davies CL, et al. Localization of anthracycline accumulation in sensitive and resistant urothelial tumor cell lines. Cancer Detect Prev 1996;20:625-33. (Pubitemid 27017074)
27. Cooper AJ, Hayes MC, Duffy PM, et al. Multidrug resistance evaluation by confocal microscopy in primary urothelial cancer explant colonies. Cytotechnology 1996;19:181-6. (Pubitemid 26324490)
28. Duffy PM, Hayes MC, Cooper A, et al. Confocal microscopy of idarubicin localisation in sensitive and multidrug-resistant bladder cancer cell lines. Br J Cancer 1996;74:906-9. (Pubitemid 26319323)
29. Belhoussine R, Morjani H, Millot JM, et al. Confocal scanning microspectrofluorometry reveals specific anthracyline accumulation in cytoplasmic organelles of multidrug-resistant cancer cells. J Histochem Cytochem 1998;46:1369-76. (Pubitemid 28555405)
30. Pignon B, et al. In vitro study of THP-doxorubicin retention in human leukemic cells using confocal laser microspectrofluorometry. Leukemia 1995;9:1361-7.
31. Chauffert B, Martin F, Caignard A, et al. Cytofluorescence localization of adriamycin in resistant colon cancer cells. Cancer Chemother Pharmacol 1984;13:14-18. (Pubitemid 14120898)
32. Kerry KK, Elizabeth HZ, Thompson JAW, et al. Deciphering the fluorescence signature of daunomycin and doxorubicin. Biophys Chem 1998;73:249-63.